Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jinxiong, Huang"'
Autor:
Hong Chen, Yan Wen, Yun Zeng, Lie Lin, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Qiang Wang, Xuan Zhou, Xiaoli Liu, Hong Qu, Zhenfang Liu, Xin Du, Na Xu
Publikováno v:
Oncology and Therapy, Vol 12, Iss 1, Pp 131-145 (2023)
Abstract Introduction Chronic myeloid leukemia (CML) is a chronic disease with treatment-free remission (TFR) increasingly regarded as a feasible goal of treatment. However, various factors may influence adherence to international guidelines for CML
Externí odkaz:
https://doaj.org/article/1a4339b229f24421b410fec79bd53d69
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTObjectives: High-risk multiple myeloma (HRMM) is associated with poor survival, despite many advances in antimyeloma strategies. Autologous followed by allogeneic stem cell transplantation (auto-allo-SCT) has yielded controversial results com
Externí odkaz:
https://doaj.org/article/055d4602c3df4a848db67cea55021842
Autor:
Chunmei Ban, Feiyan Yang, Min Wei, Qin Liu, Jiankun Wang, Lei Chen, Liuting Lu, Dongmei Xie, Lie Liu, Jinxiong Huang
Publikováno v:
Frontiers in Genetics, Vol 12 (2021)
Tumor progression includes the obtainment of progenitor and stem cell-like features and the gradual loss of a differentiated phenotype. Stemness was defined as the potential for differentiation and self-renewal from the cell of origin. Previous studi
Externí odkaz:
https://doaj.org/article/44bb5a26b03b4a1b9c84949b1c94b0bb
Autor:
Yiren Zhang, Xuejun Wen, Yanjie Wang, Xia Yang, Yingxi Chen, Xinying Zeng, Yesen Li, Jinxiong Huang, Zhide Guo, Xianzhong Zhang
Publikováno v:
Molecular Pharmaceutics. 20:473-480
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::495eb14a70f66159624f461bee8ede0b
https://doi.org/10.1021/acs.molpharmaceut.2c00717
https://doi.org/10.1021/acs.molpharmaceut.2c00717
Autor:
Lanlin Yao, Xuejun Wen, Wei Guo, Jianyang Fang, Xianzhong Zhang, Zhide Guo, Jinxiong Huang, Yesen Li
Publikováno v:
Molecular Pharmaceutics. 19:3178-3186
Currently, the 5-year survival rate for patients with advanced hepatocellular carcinoma (HCC) is very low. Therefore, there is an urgent need to find new strategies for the treatment of HCC. TMTP1 (NVVRQ) is a tumor-homing peptide that has been shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::175ff86eb10065bfb314a928a92da88f
https://doi.org/10.1021/acs.molpharmaceut.2c00270
https://doi.org/10.1021/acs.molpharmaceut.2c00270
Autor:
Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang, Zhide Guo, Xiaoyuan Chen, Xianzhong Zhang
Publikováno v:
Molecular Pharmaceutics. 19:3612-3622
Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5776014ee9dbb01e9be6a53d32bdba1
https://doi.org/10.1021/acs.molpharmaceut.2c00281
https://doi.org/10.1021/acs.molpharmaceut.2c00281
Autor:
Zhide Guo, Xianzhong Zhang, Xiaoyuan Chen, Rongqiang Zhuang, Haojun Chen, Qin Lin, Yesen Li, Jinxiong Huang, Deliang Zhang, Lixia Feng, Zhida Liu, Lanlin Yao, Liang Zhao, Xinying Zeng, Changrong Shi, Xuejun Wen
Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391be57421e2b0b7dd570153025cc958
https://doi.org/10.1158/1078-0432.22486374.v1
https://doi.org/10.1158/1078-0432.22486374.v1
Autor:
Zhide Guo, Xianzhong Zhang, Xiaoyuan Chen, Rongqiang Zhuang, Haojun Chen, Qin Lin, Yesen Li, Jinxiong Huang, Deliang Zhang, Lixia Feng, Zhida Liu, Lanlin Yao, Liang Zhao, Xinying Zeng, Changrong Shi, Xuejun Wen
Purpose:Efforts have been devoted to select eligible candidates for PD-1/PD-L1 immune checkpoint blocker (ICB) immunotherapy. Here, we have a serendipitous finding of positron emission tomography (PET) imaging tracer 2-[18F]FDG as a potential immunom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318e9b729c3a954542231feddad64e03
https://doi.org/10.1158/1078-0432.c.6532302
https://doi.org/10.1158/1078-0432.c.6532302
Autor:
Xiao Xu, Hu Chen, Pan He, Zhenwen Zhao, Xing Gao, Chao Liu, Hongwei Cheng, Lai Jiang, Peiyu Wang, Yang Zhang, Xiaofei Wen, Yesen Li, Jinxiong Huang, Yongfu Xiong, Jingsong Mao, Hongjuan Ma, Gang Liu
Publikováno v:
Advanced Functional Materials. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37d63124825bcfa036b35773108bca93
https://doi.org/10.1002/adfm.202215110
https://doi.org/10.1002/adfm.202215110
Autor:
Xiaoru Lin, Duo Xu, Yesen Li, Jinxiong Huang, Zhide Guo, Xuejun Wen, Xiaoyuan Chen, Xianzhong Zhang, Xinying Zeng, Jingchao Li
Publikováno v:
Analytical Chemistry. 93:13998-14006
Overexpression of estrogen receptors (ERs) is one of the important characteristics of most breast cancers. We aim to develop a new type of ER-specific radioiodine-labeled estrogen derivative ([131I]IPBA-EE), which was modified with an albumin-specifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d096504866c2eab1a81c611d7c94ee2
https://doi.org/10.1021/acs.analchem.1c03616
https://doi.org/10.1021/acs.analchem.1c03616